Taiga Nishihori, MD, Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the results from the Phase II BMT CTN 1302 trial (NCT02440464) of maintenance ixazomib after allogeneic hematopoietic cell transplantation in patients with high-risk multiple myeloma. Fludarabine, melphalan and bortezomib were administered as a conditioning treatment and 12 rounds of ixazomib or placebo maintenance were administered after transplant. Dr Nishihori reports no significant progression-free survival (PFS) or overall survival (OS) between the ixazomib and placebo groups. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.